Rotavirus Vaccine Coverage Rate Rose to 72% Nationwide

2010 ◽  
Vol 44 (9) ◽  
pp. 12
Author(s):  
DOUG BRUNK
Keyword(s):  
Vaccine Coverage ◽  
Coverage Rate ◽  
Rotavirus Vaccine

scholarly journals Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh

2019 ◽  
Vol 69 (12) ◽  
pp. 2059-2070 ◽  
Author(s):  
Lauren M Schwartz ◽  
K Zaman ◽  
Md Yunus ◽  
Ahasan-ul H Basunia ◽  
Abu Syed Golam Faruque ◽  
...  
Keyword(s):  
Vaccine Coverage ◽  
Controlled Trial ◽  
Population Level ◽  
Diarrhoeal Disease ◽  
Incidence Rates ◽  
Service Area ◽  
Rotavirus Vaccine ◽  
Rotavirus Vaccines ◽  
Time Period ◽  
The Impact

Abstract Background Following the conclusion of a human rotavirus vaccine (HRV) cluster-randomized, controlled trial (CRT) in Matlab, Bangladesh, HRV was included in Matlab’s routine immunization program. We describe the population-level impact of programmatic rotavirus vaccination in Bangladesh in children <2 years of age. Methods Interrupted time series were used to estimate the impact of HRV introduction. We used diarrheal surveillance collected between 2000 and 2014 within the 2 service delivery areas (International Centre for Diarrhoeal Disease Research, Bangladesh [icddr,b] service area [ISA] and government service area [GSA]) of the Matlab Health and Demographic Surveillance System, administered by icddr,b. Age group–specific incidence rates were calculated for both rotavirus-positive (RV+) and rotavirus-negative (RV–) diarrhea diagnoses of any severity presenting to the hospital. We used 2 models to assess the impact within each service area: Model 1 used the pre-vaccine time period in all villages (HRV– and control-only) and Model 2 combined the pre-vaccine time period and the CRT time period, using outcomes from control-only villages. Results Both models demonstrated a downward trend in RV+ diarrheal incidences in the ISA villages during 3.5 years of routine HRV use, though only Model 2 was statistically significant. Significant impacts of HRV on RV+ diarrhea incidences in GSA villages were not observed in either model. Differences in population-level impacts between the 2 delivery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the hospital. Conclusions This study provides initial evidence of the population-level impact of rotavirus vaccines in children <2 years of age in Matlab, Bangladesh. Further studies are needed of the rotavirus vaccine impact after the nationwide introduction in Bangladesh.

scholarly journals Factors Associated With Rotavirus Vaccine Coverage

PEDIATRICS ◽  
2019 ◽  
Vol 143 (2) ◽  
pp. e20181824 ◽  
Author(s):  
Negar Aliabadi ◽  
Mary E. Wikswo ◽  
Jacqueline E. Tate ◽  
Margaret M. Cortese ◽  
Peter G. Szilagyi ◽  
...  
Keyword(s):  
Vaccine Coverage ◽  
Rotavirus Vaccine ◽  
Factors Associated

scholarly journals Diarrheal Diseases Hospitalization in Yemen before and after Rotavirus Vaccination

Scientifica ◽  
2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Mohammed Amood AL-Kamarany ◽  
Lina Al-Areqi ◽  
Abulatif Mujally ◽  
Fawzya Alkarshy ◽  
Arwa Nasser ◽  
...  
Keyword(s):  
Vaccine Coverage ◽  
Rotavirus Vaccine ◽  
Diarrheal Diseases ◽  
Predominant Genotype ◽  
Fecal Samples ◽  
Vaccine Introduction ◽  
Rotavirus Vaccination ◽  
Before And After ◽  
Rotavirus Diarrhea ◽  
The Impact

The study aims to assess the impact of rotavirus vaccine introduction on diarrheal diseases hospitalization and to identify the rotavirus genotypes most prevalent before and after vaccine introduction among children ≤ 5 years of age. Rotarix™® rotavirus vaccine is currently licensed for infants in Yemen and was introduced in 2012. The vaccination course consists of two doses. The first dose is administrated at 6 weeks of age and the second dose is completed by 10 weeks. Based on a longitudinal observational study, we assessed the impact of vaccination on rotavirus hospitalization before and after vaccination among children ≤ 5 years of age at the Yemeni-Swedish Hospital (YSH) in Taiz, Yemen. Prevaccination covered January 2009–July 2012 during which 2335 fecal samples were collected from children ≤ 5 years old. Postvaccination covered January 2013–December 2014 during which 1114 fecal samples were collected. Rotavirus was detected by Enzyme Linkage Immunosorbent Assay (ELISA). The incidence ofrotavirushospitalization decreased from 43.79% in 2009 to 10.54% in 2014. Hospitalization due to rotavirus diarrhea was reduced by 75.93%. Vaccine coverage increased from 23% in 2012 to 72% in 2014. Also, the results showed that the most predominant genotypes in prevaccination period were G2P[4] (55.0%), followed by G1P[8] (15.0%), while in postvaccination period G1P[8] (31%) was the predominant genotype, followed by G9P[8] (27.5%). In conclusion, rotavirus vaccination in Yemen resulted in sharp reduction in diarrheal hospitalization. A successful rotavirus vaccination program in Yemen will rely upon efficient vaccine delivery systems and sustained vaccine efficacy against diverse and evolving rotavirus strains.

scholarly journals TETANUS IMMUNIZATION AMONG PREGNANT WOMEN: COVERAGE RATE AND RATE OF PROTECTION AT TIME OF DELIVERY

2019 ◽  
Author(s):  
Zamzam Ali Hezam Saleh Aljedry ◽  
Alia A. Shaib ◽  
Hassan A H. Al-Shamahy ◽  
Ahmed Y. Al-Jaufy
Keyword(s):  
Pregnant Women ◽  
Vaccine Coverage ◽  
Serum Antibody ◽  
Coverage Rate ◽  
Childhood Vaccination ◽  
Neonatal Tetanus ◽  
Serum Samples ◽  
Igg Antibody ◽  
Cross Sectional ◽  
Tetanus Immunization

Even though attempts have been effectively applied to eradicate the neonatal tetanus through widespread childhood vaccination and improved conditions at delivery, it remains major cause of infant mortality and continues a problem of public health in developing countries including Yemen.  The aims of this study were to determine the tetanus immunization status, the association between the risk factors and failure of protection in pregnant women at time of delivery. This cross-sectional study included 476 women seeking care for delivery at Al Thawra Modern General Hospital and Al Sabain Hospital, women age ranged from 16-49 years old. Immunization information and factors affecting it were obtained through a standard questionnaire. Serum samples were collected and level of IgG antibody against Clostridium tetani was measured by ELISA technique. Protected women were defined as those with serum antibody levels > or = 0.6 IU/ml.  The total vaccine covering rate of tetanus was 87%, and  maternal vaccine rate was 33.6%, the protective rate at time of delivery was 68.5%. There were significant association between  unvaccinated (OR=18.6), older ages (OR=1.7), rural residency (OR=34) and malaria infection during pregnancy (OR=2.9); with protection failure in pregnant women at time of delivery. It can be concluded that the total vaccine coverage rate and antenatal tetanus vaccine rate were insufficient. In addition, the protective rate at time of delivery was low and large numbers of neonate are susceptible to neonatal tetanus and death. Vaccinating every pregnant woman with at least one dose of TT would be an affordable and effective way to protect against neonatal tetanus, and would be a step toward eliminating the deaths that continue to occur due to this preventable disease in Yemen.

scholarly journals Rotavirus symptomatic infection among unvaccinated and vaccinated children in Valencia, Spain

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Raúl Pérez-Ortín ◽  
Cristina Santiso-Bellón ◽  
Susana Vila-Vicent ◽  
Noelia Carmona-Vicente ◽  
Jesús Rodríguez-Díaz ◽  
...  
Keyword(s):  
Vaccine Coverage ◽  
National Health System ◽  
Epidemiological Data ◽  
Immunological Methods ◽  
Rotavirus Vaccine ◽  
Symptomatic Infection ◽  
Rotavirus Infection ◽  
Rotavirus Vaccination ◽  
Group A ◽  
Rotavirus Infections

Abstract Background Human group A rotavirus is the leading cause of severe acute gastroenteritis in young children worldwide. Immunization programs have reduced the disease burden in many countries. Vaccination coverage in the Autonomous Region of Valencia, Spain, is around 40%, as the rotavirus vaccine is not funded by the National Health System. Despite this low-medium vaccine coverage, rotavirus vaccination has substantially reduced hospitalizations due to rotavirus infection and hospital-related costs. However, there are very few studies evaluating symptomatic rotavirus infections not requiring hospitalization in vaccinated children. The objective of this study was to investigate symptomatic rotavirus infections among vaccinated children in the health area served by the Hospital Clínico Universitario of Valencia, Spain, from 2013 to 2015. Methods A total of 133 children younger than 5 years of age with rotavirus infection were studied. Demographic and epidemiological data were collected and informed consent from their caretakers obtained. Rotavirus infection was detected by immunological methods and G/P rotavirus genotypes were determined by RT-PCR, following standard procedures from the EuroRotaNet network. Results Forty infants (30.1%; 95% CI: 22.3–37.9) out of 133 were diagnosed with symptomatic rotavirus infection despite having been previously vaccinated, either with RotaTeq (85%) or with Rotarix (15%). Children fully vaccinated against rotavirus (24.8%), partially vaccinated (5.3%) and unvaccinated (69.9%) were found. The infecting genotypes showed high G-type diversity, although no significant differences were found between the G/P genotypes infecting vaccinated and unvaccinated children during the same time period. G9P[8], G12P[8] and G1P[8] were the most prevalent genotypes. Severity of gastroenteritis symptoms required 28 (66.6%) vaccinated and 67 (73.6%) unvaccinated children to be attended at the Emergency Room. Conclusion Rotavirus vaccine efficacy in reducing the incidence of severe rotavirus infection has been well documented, but symptomatic rotavirus infection can sometimes occur in vaccinees.

scholarly journals Impact of Rotavirus Vaccine on Premature Infants

2014 ◽  
Vol 21 (10) ◽  
pp. 1404-1409 ◽  
Author(s):  
Jean-Michel Roué ◽  
Emmanuel Nowak ◽  
Grégoire Le Gal ◽  
Thomas Lemaitre ◽  
Emmanuel Oger ◽  
...  
Keyword(s):  
Premature Infants ◽  
Vaccine Coverage ◽  
Vaccination Campaign ◽  
University Hospital ◽  
Vaccination Program ◽  
National Study ◽  
Rotavirus Vaccine ◽  
Term Infants ◽  
Rotavirus Diarrhea ◽  
The Impact

ABSTRACTInfants born preterm are at a higher risk of complications and hospitalization in cases of rotavirus diarrhea than children born at term. We evaluated the impact of a rotavirus vaccination campaign (May 2007 to May 2010) on hospitalizations for rotavirus gastroenteritis in a population of children under 3 years old born prematurely (before 37 weeks of gestation) in the Brest University Hospital birth zone. Active surveillance from 2002 to 2006 and a prospective collection of hospitalizations for rotavirus diarrhea were initiated in the pediatric units of Brest University Hospital until May 2010. Numbers of hospitalizations for rotavirus diarrhea among the population of children born prematurely, before and after the start of the vaccination program, were compared using a Poisson regression model controlling for epidemic-to-epidemic variation. A total of 217 premature infants were vaccinated from 2007 to 2010. Vaccine coverage for a complete course of three doses was 41.9%. The vaccine safety in premature infants was similar to that in term infants. The vaccination program led to a division by a factor of 2.6 (95% confidence interval [CI], 1.3 to 5.2) in the number of hospitalizations for rotavirus diarrhea during the first two epidemic seasons following vaccine introduction and by a factor of 11 (95% CI, 3.5 to 34.8) during the third season. We observed significant effectiveness of the pentavalent rotavirus vaccine on the number of hospitalizations in a population of prematurely born infants younger than 3 years of age. A multicenter national study would provide better assessment of this impact. (This study [Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France (IVANHOE)] has been registered at ClinicalTrials.gov under registration no. NCT00740935.)

Sign in / Sign up

Export Citation Format

Share Document